Molecular profiling of the tumor was remarkable for PPFIBP1-ALK translocation...However, she experienced progression on alectinib after 5 months and was placed back on FOLFIRINOX. Subsequent cell-free plasma...showed newly acquired ALK mutations G1202R and V1180L in addition to the PPFIBP1-ALK translocation. The patient experienced progression quickly on FOLFIRINOX and was transitioned to lorlatinib. The patient’s disease has been stable on lorlatinib on 2-month follow-up imaging, and she continues to be treated with lorlatinib.